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ASSESSMENT PROCEDURES
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ABSTRACT
Purpose: This study assessed the validity of the shuttle walk test (SWT) to evaluate walking ability in
patients with polyneuropathy.
Methods: Forty-one patients with chronic idiopathic axonal polyneuropathy (CIAP) and 49 patients with
multifocal motor neuropathy (MMN) performed both the 10-meter walk test (10MWT) and the SWT. Face
validity was assessed by evaluating whether patients considered both tests to reflect their walking ability
(Likert scale: 1¼not at all, 10¼ very well). Concurrent validity was determined by Spearman rank-correl-
ation analyses performed on the outcomes of both tests.
Results: Mean (SD) scores for how well the 10MWT and SWT reflected daily walking ability were 6.8 (1.3)
and 7.4 (1.6) (p¼ 0.117) in patients with CIAP and 6.9 (1.2) and 7.9 (1.0) (p¼ 0.001) in patients with MMN,
respectively. Correlation scores between both tests ranged from 0.70 to 0.82, except for 18 patients
with MMN with a “normal” walking speed at the 10MWT (0.21).
Conclusion: The SWT seems a valid instrument for assessing walking ability in individuals with CIAP and
MMN. Moreover, the SWT seems to be useful for investigating the symptoms elicited by walking long dis-
tances and may be more sensitive to changes when compared to the 10MWT.
 IMPLICATIONS FOR REHABILITATION
 Patients with polyneuropathy mainly experience problems when walking long distances.
 The 10-meter walk test does not possess sufficient psychometrics to diagnose walking abilities in
these circumstances.
 The shuttle walk test is a valid instrument for assessing walking ability in individuals with polyneur-
opathy and might be the preferred instrument of choice when compared to the 10-meter walk
test.
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One of the major problems of individuals with polyneuropathy is
their limited walking ability,[1–4] which is usually progressive. The
generic 10-meter walk test (10MWT) [5,6] is frequently used [7–13]
to measure walking ability, since there is no “true” gold standard
method for assessing walking ability in a performance-based man-
ner. Clinically, however, we often experience that individuals with
polyneuropathy perform the 10MWT with ease and only experi-
ence problems when walking long distances. Consequently, the
10MWT often shows ceiling effects,[2,9,10,13] implicating that the
walking ability of individuals over short distances (10 m) is com-
parable to that of healthy adults.[14,15] Moreover, the responsive-
ness of the 10MWT in individuals with inflammatory
polyneuropathy was shown to be poor.[9]
Hence, an extended walking test, such as the incremental shut-
tle walk test (SWT), may be more appropriate for assessing their
walking ability.[2] The SWT was developed to measure the func-
tional capacity, expressed in maximal walking distance, of
individuals with chronic airway obstruction.[16] Nowadays, its
clinimetric properties have been established in individuals with
chronic heart failure and those with chronic respiratory diseases.
[17,18] Reference values for maximal walking distance on the SWT
have been established for healthy individuals.[19,20] The valid-
ation of this test for measuring walking ability of patients with
polyneuropathy requires assessment of both functional capacity
and walking ability, to ensure that the patients’ walking perform-
ance reflects limitations due to their neurological disease rather
than, for example, impaired cardiopulmonary fitness. We have pre-
viously found the SWT to be feasible in individuals with chronic
idiopathic axonal polyneuropathy (CIAP) and multifocal motor
neuropathy (MMN).[3,21,22] CIAP is a slowly progressive distal
symmetric sensory or sensorimotor polyneuropathy with axonal
degeneration that mainly affects the legs. In these individuals,
known causes of polyneuropathy have been excluded by exten-
sive laboratory examination. The mean age at onset of CIAP is
57 years, with a male predominance.[10,23] MMN is a chronic
immune-mediated neuropathy characterized by slowly
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progressive, predominantly distal asymmetric limb weakness, in
the arms more than the legs, not accompanied by sensory loss.
The mean age at onset is 40 years, with a male predominance.[24]
The aim of this cross-sectional study was to assess face validity
and concurrent validity of the SWT for the evaluation of walking
ability of patients with CIAP and patients with MMN.
Methods
Participants
Forty-one clinically stable patients diagnosed with CIAP and
49 clinically stable patients diagnosed with MMN who attended
the outpatient clinic of the Department of Neuromuscular
Diseases of the University Medical Center Utrecht between 2007
and 2009 for their annual checkup participated in this study. CIAP
and MMN were chosen because our department is a referral cen-
ter for patients with these disorders, many of whom participate in
long-term, follow-up research. All participants gave informed con-
sent. Data collection, analysis, and publication were approved by
the ethics committee of the University Medical Center Utrecht.
Study design
The study had a cross-sectional design. The participants came to
the gymnasium of the outpatient clinic, where demographic data,
comorbidities, medication use, and the use of walking aids were
recorded and they were classified into (dis)ability subgroups, using
the 5-class modified Rankin scale.[25] To assess concurrent validity
of the incremental SWT, the participants performed both the
10MWT and the incremental SWT. There was a five-minute interval
between the tests to allow the participants to recover. Face valid-
ity of the incremental SWT was assessed by means of participant
interviews after completion of the two walking tests. The partici-
pants were asked: “How well does the 10MWT and the SWT reflect
your walking ability in daily life? Please score each test, with
scores ranging from 1 (not at all) to 10 (very well)”. All measure-
ments were performed by a physical therapist (PGE) who has
more than 10 years of clinical experience with these patient
groups and with the various tests used.
Measurements
10-Meter walk test
For the 10MWT, all participants were asked to walk a 10-meter
course from standing still, at their preferred walking speed, using
a walking aid if needed.[5] The time needed to walk the distance
was recorded using a stopwatch. They started walking after a
countdown, and the physical therapist, for safety and support rea-
sons, walked slightly behind the participant. The test and timing
stopped immediately when a participant stepped onto or over the
ten-meter line. We calculated the mean time scores of three
assessments. Normative data for walking speed have been deter-
mined for healthy adults.[14,15]
Incremental shuttle walk test
When walking the incremental SWT, the participants were asked
to walk around a 10-meter course marked by two cones placed
nine meters apart, thus allowing half a meter for turning round at
each end (Figure 1). Walking speed was regulated by prerecorded
metronomic signals from a standard CD player. The participant
was asked to walk around the cones at each signal. In the original
version of the SWT, the initial walking speed of 1.8 km/h (0.50 m/
s) increases by 0.6 km/h (0.17 m/s) every minute up to a maximum
walking speed of 8.5 km/h (2.37 m/s). We used a modified version
of the SWT (see appendix) in which the initial walking speed of
3.0 km/h (0.83 m/s) was increased by 0.5 km/h (0.14 m/s) every
two minutes up to a maximum walking speed of 7.0 km/h
(1.94 m/s).[26] This modification was made in order to allow par-
ticipants to adapt to walking at each speed and thus probably
better mimics walking long distances in daily life. Standardized
instructions were given prior to the test and participants were
encouraged to walk as long as possible (maximal effort) without
risking falling. The use of walking aids (including orthopedic shoes
and ankle-foot orthoses) was permitted. Again, the physical ther-
apist, for safety and support reasons, walked slightly behind the
individual. The test was terminated by the physical therapist if the
participant’s foot was not on or within a line placed half a meter
from the cone at the prerecorded signal for three consecutive
shuttles. Moreover, the test was terminated whether the partici-
pant stopped walking for whatever reason, or when the partici-
pant completed the entire test (i.e., 150 times the 10-meter
course). The number of shuttles (i.e., 10-meter courses) was the
primary outcome measure of the SWT in which higher numbers
are indicative of a better walking ability, with a maximum of
1500 m (see appendix). In addition, heart rate and perceived exer-
tion (Borg scale) were measured before and immediately after the
incremental SWT. The Borg scale [27] is a 11-point Likert scale for
perceived exertion, with scores ranging from 0 (“nothing at all”) to
10 (“very, very strong”).
Statistical analysis
All data were expressed as mean± SD or median (range) and anal-
yses were performed using the Statistical Package for the Social
Sciences version 15.0 (SPSS Inc., Chicago, IL). Data were tested for
normality using Kolmogorov–Smirnov tests. Face validity of the
incremental SWT was assessed by evaluating whether patients
Figure 1. The shuttle walk test.
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considered the 10MWT and SWT to reflect their walking ability at
a 10-point Likert scale (1¼not at all, 10¼ very well). Data on the
symptoms experienced by the participants after completing the
SWT were analyzed. Concurrent validity of the incremental SWT
was assessed using Spearman’s rank correlation analysis between
the main outcome parameter of the 10MWT (mean time to com-
plete the 10-meter distance) and the main outcome parameter of
the incremental SWT (the number of completed shuttles).
Moreover, both groups were categorized into individuals who had
normative time scores on the 10MWT (“normal” walkers), and
those who had higher than normative time scores on the 10MWT
(“slow” walkers). Participants were assumed to be “normal” walkers
whenever their time scores were within two standard deviations
of the mean normative score [14] or within the 95% confidence
interval.[15] In this way, it would be possible to assess the discrim-
inative properties of the incremental SWT (group validity), as well
as to detect differences in correlation coefficients between the
two groups, and hence differences in the assessment of walking
ability with the two tests. A priori, it was inferred that the SWT
might be particularly clinically useful for assessing the walking
ability of individuals who walk at normal speed on the 10MWT.
Differences in correlation coefficients between the two groups
were investigated with bootstrap analysis.[28] Walking ability
might be influenced by sex, age, height, and the use of walking
aids. Subanalysis by means of hierarchical multiple univariate lin-
ear regression analysis (enter procedure) was, therefore, carried
out to investigate the contribution of each of these determinants.
To this end, the outcome on the SWT was used as dependent
variable and the outcome on the 10MWT, sex, age, height, and
walking aids as independent variables. With help of the linear
regression analysis, the relative importance of the independent
variables is expressed as a statistically significant standardized
beta coefficient. All tests were two-sided and p values <0.05 were
considered statistically significant.
Results
A total of 47 patients with CIAP and 49 patients with MMN were
included in this study. Six participants with CIAP were excluded
from the study, since they were unable to perform the SWT
because of neuropathic pain in the lower legs or feet (n¼ 5) or
impaired balance (n¼ 1). All excluded participants used walking
aids. The mean (SD) 10MWT score of the excluded individuals was
24.9 (9.5) s, which was significantly higher than the 10MWT score
of the participants in the CIAP study group who also performed
the SWT (9.7 (2.5) s) (p< 0.05). In the MMN group, all participants
were able to perform the SWT.
Demographics, comorbidity, and the use of walking aids are
presented in Table 1. About two-thirds of the participants were
classified as Rankin 2, that is, “slight disability: unable to carry out
all previous activities but able to look after own affairs without
assistance”. Five participants with CIAP (12%) and one with MMN
(2%) had two or more comorbidities. Four participants with CIAP
(10%) and two with MMN (4%) were taking beta-adrenergic block-
ing agents. Five participants with CIAP (12%) and two with MMN
(4%) used a combination of orthopedic shoes/ankle-foot orthoses
and walking aids.
Test results are presented in Table 2. One participant with CIAP
and one participant with MMN were able to walk a maximum of
10 m (one shuttle) during the SWT. Six participants with CIAP
(13%) and six participants with MMN (12%) completed all 150
shuttles on the SWT. Nine participants with CIAP (22%) and 18
participants with MMN (37%) scored<8 s on the 10MWT. Mean
(SD) scores for how well the 10MWT and SWT reflected daily
walking ability were 6.8 (1.3) and 7.4 (1.6) (p¼ 0.117) in patients
with CIAP and 6.9 (1.2) and 7.9 (1.0) (p¼ 0.001) in patients with
MMN, respectively. The distribution of walking test scores for each
group, including linear line fit, are shown in Figures 2, 3, and 4.
Face validity
The Likert scores for how well the 10MWT and the SWT reflected
daily walking ability are presented in Table 2. In general, the
majority of the participants (58% with CIAP and 59% with MMN)
considered the SWT to better reflect their daily walking ability
than the 10MWT: these participants had mean (SD) time scores on
the 10MWT of 8.9 (2.2) and 8.1 (1.3) s, respectively. Additionally,
all these participants stated that the symptoms they experienced
after completion of the SWT were similar to those experienced in
daily life. This was not the case for the 10MWT. In contrast, 35%
of the participants with CIAP and 20% of the participants with
MMN considered the 10MWT to better reflect their daily walking
ability than the SWT; they had mean (SD) time scores on the
10MWT of 11.2 (2.4) and 9.4 (3.4) s, respectively. The remaining
participants with CIAP and MMN considered both tests to reflect
their walking ability equally.
Twenty-three (56%) participants with CIAP and 24 (49%) with
MMN felt that their legs “blocked” after termination of the SWT,
that is, they could not move their legs any faster, but did not
experience this as a natural transition to running (Table 2).
Another symptom was a sensation of fatigue in the legs, which
was mentioned by six participants with CIAP (15%) and by five
participants with MMN (10%). Only one participant (heart rate
at the end of the SWT of 124 beats/min [73% of the predicted
maximal heart rate]) stopped the test because of perceived
Table 1. Participant characteristics.
Demographics CIAP n¼ 41 MMN n¼ 49
Age (y) 66.2 (9.6) 51.5 (11.1)
Sex (m/f) 30/11 35/14
Disease duration (y) 6.5 (5.3) 2.0 (0.6)









Angina pectoris 2 1
Valvular heart disease 0 2
COPD 3 3
Diabetic 0 1
Ankylosing spondylitis 0 1
Lumbar disc herniation 5 1
Low back pain 2 1
Total hip prothesis 2 0
Cruciate ligament/meniscus 1 2
Ankle fracture 0 1
Cerebrovascular incident 1 0
Depression 3 0
Walking aids
Ankle-foot orthosis 6 7
Orthopedic shoes 5 3
Walking cane 8 0
Crutch 1 0
Rollator 2 1
CIAP: chronic idiopathic axonal polyneuropathy; MMN: multifocal motor
neuropathy.
Values are expressed as means (SD) or as frequencies.
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exhaustion (Table 2). The six participants in each group who were
able to complete the SWT did not report walking disability in
daily life.
Concurrent validity
Table 3 shows the correlation coefficients between 10MWT scores
and SWT scores for the “normal” walkers and the “slow” walkers
(see statistical analysis). The correlation coefficients were high for
all participants with CIAP (Spearman’s r values ranging from 0.82
to 0.83) and for “slow” walkers with MMN (Spearman’s r value
0.70). This means that participants who walked faster on the
10MWT walked further (more shuttles) on the SWT. The correl-
ation was low (Spearman’s r value 0.21) for the participants with
MMN who walked at “normal” (i.e., normative) speed.
Hierarchical multiple univariate linear regression analysis
showed that the 10MWT and age had significant beta values of
0.66 and 0.20 in the CIAP group, and 0.53 and 0.33 in the
MMN group. The beta values for sex, body height, disease dur-
ation, and the use of walking aids were less than 0.10. Therefore,
only 10MWT score and age contributed significantly to the
explained variance in SWT score.
Discussion
To our knowledge, this is the first detailed study to assess the val-
idity of the SWT in evaluating walking ability in individuals with
polyneuropathy. Walking ability was successfully assessed with the
SWT, without apparent large floor and ceiling effects. Moreover,
the SWT demonstrated that most participants with CIAP and MMN
had walking disability and related symptoms. These problems
were not expected in participants with MMN, because these
patients typically have major problems with dexterity, not walking
ability.[2] Overall, SWT scores correlated well with 10MWT scores.
The participants considered the SWT to best reflect their daily
walking ability, and the symptoms they experienced after perform-
ing the SWT mimicked those experienced in daily life. Thus the
SWT would appear to be a clinically useful instrument for assess-
ing walking ability in individuals with polyneuropathy.
Up till now, questionnaires have been designed to assess the
walking ability of individuals with polyneuropathy.[4] However,
the participants’ rating of their performance may differ quite a bit
from their actual performance.[3,29] Therefore, performance-based
instruments such as the 10MWT and, based on this study, espe-
cially the SWT can be used to measure the walking ability of
patients with polyneuropathy. An alternative performance-based
test might be the 6-min walk test. This test was originally devel-
oped to assess functional capacity and has been used to assess
the walking ability of individuals with diabetic neuropathy.[30] We
chose the SWT because the patients encountered walking disabil-
ity after walking long distances. The 6-min walk test lasts only six
minutes, whereas the SWT may last up to 18min. Therefore, it is
more likely that patients encounter their problems walking long
distances at the SWT.
In this study, we did not examine in detail the nature of the
symptoms as experienced by the participants after the SWT.
Table 2. 10MWT and SWT results.
Test CIAP n¼ 41 MMN n¼ 49
10MWT
Time score (sec) 9.7 (2.5) 8.6 (2.1)
Representativeness of test (0–10 points) 6.8 (1.3) 6.9a (1.2)
SWT
Shuttle score (n) 62.6 (46.9) 90.1 (41.9)
Representativeness of test (0–10 points) 7.4 (1.6) 7.9a (1.0)
Reason for stopping (n)
Did not reach cone 32 37
Test completed 6 6
Patient stopped 3 6
Symptoms when stopping (n)
Legs “blocked” 23 24
Fatigue legs 6 5
Balance/stumbling 0 3
Painful legs 4 0
Muscle strength impairment 0 3
Legs cramps 0 1
Normal transition to running 1 6
Fall 1 0
Exhaustion 0 1
No complaints (i.e., test completed) 6 6
Heart rate before SWT (beats/min) 73.2 (13.4) 71.7 (10.8)
Heart rate after SWT (beats/min)/%predicted 103.8/64% 111.9/65%
(20.0)/(12%) (18.7)/(10%)
Exertion before SWT (Borg score 0–10 points) 2 (0–8) 1 (0–4)
Exertion after SWT (Borg score 0–10 points) 4 (1–10) 3 (1–7)
10MWT: 10-meter walk test; SWT: shuttle walk test; CIAP: chronic idiopathic
axonal polyneuropathy; MMN: multifocal motor neuropathy
Values are expressed as means (SD) or as medians (range), unless stated
otherwise.
aSignificant difference (p¼ 0.001) between the scores for the 10MWT and SWT
in persons with MMN.
Figure 2. Relation between the 10MWT and the SWT in participants with CIAP
(n¼ 41). 10MWT¼ 10-meter walk test, SWT¼ shuttle walk test, ¼ participants
walking at a normative speed during the 10MWT, w ¼ participants walking
slower than the normative speed during the 10MWT, r ¼ Spearman’s r.
Figure 3. Relation between the 10MWT and the SWT in participants with MMN
(n¼ 49). 10MWT¼ 10-meter walk test, SWT¼ shuttle walk test, ¼ participants
walking at a normative speed during the 10MWT, w ¼ participants walking
slower than the normative speed at the 10MWT, r¼ Spearman’s r.
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“Blocking legs”, which was frequently mentioned by the partici-
pants, may have been caused by their neural pathology, but may
also have been caused by an impaired oxidative capacity of the
muscles due to deconditioning, medication use, aging, or poor
nutritional status, as has been described in patients with lung
transplantation.[31] Additional research is warranted to investigate
the association between participants’ symptoms during the SWT
and their neuropathology. Post hoc analysis showed that only
three participants with CIAP and four participants with MMN had
a heart rate at the end of the SWT>80% of their predicted max-
imal heart rate [32], meaning that most participants in this study
did not exerted themselves maximally during the SWT and that
the SWT was a symptom-limited test. Only one patient stopped
the SWT due to exhaustion, and mean post-test Borg scale scores
for perceived exertion were low. We did not encourage the
patients during the SWT. Encouragement is frequently used in the
assessment of functional exercise capacity, and the assessment of
functional exercise capacity was not the aim of this study.
Compared to the 10MWT time scores, the SWT time scores of
the 27 “normal” walkers showed substantial variation in both
groups (a range of 1.5 s on the 10MWT and a range of nearly 60 s
on the SWT) (Figure 3). Thus, the SWT may be more sensitive to
changes and therefore might serve as a test to evaluate therapy
or to collect longitudinal data in individual patients in order to
measure disease progression. This, however, needs to be con-
firmed in a properly performed sensitivity-to-change study.[33] It
was not possible to measure the SWT performance of very slow
walking subjects who took longer than 12 s to complete the
10MWT; when walking the SWT they did not reach the first cone
in time. Future studies should investigate whether a starting walk-
ing speed on the SWT of 2.0 km/h or 2.5 km/h is more appropriate
for these patients.
A limitation of this study is the absence of a true gold standard
for assessing walking ability over long distances. Secondly, 12 par-
ticipants were able to walk all 150 shuttles on the SWT. An
extended SWT with higher walking speed might have avoided this
ceiling effect. Bear in mind that with higher walking speeds partic-
ipants might need to run. Finally, we did not measure oxygen sat-
uration in our participants and the heart rate assessment was
performed manually.
This study showed that the SWT is useful for measuring walking
ability in individuals with CIAP and MMN, especially in those whose
time scores on the 10MWT are the same as healthy controls (i.e.,
time scores<9 s on the 10MWT), since the 10MWT does not pos-
sess sufficient discriminative power in these individuals. Moreover,
the SWT seems to be useful for investigating the symptoms elicited
by walking long distances. The 10MWT may be helpful to assess
walking ability during short walks, and when time scores>9 s are
expected. The SWT may serve as a performance-based diagnostic
test and help to guide tailoring of immunological and rehabilitation
interventions.[34] The SWT may also be useful in other polyneuro-
pathies and may be complementary to validated tests recom-
mended by the European Inflammatory Neuropathy Cause and
Treatment Group (INCAT) study group.[35] Future studies should
assess the reliability and responsiveness of the SWT and establish
disease-specific reference values for patients with polyneuropathies
and healthy males and females of different ages.
Conclusion
In this study, we established the face validity and concurrent val-
idity of the SWT for assessing walking ability of individuals with
CIAP and MMN. Moreover, the SWT seems to be useful for investi-
gating the symptoms elicited by walking long distances, and may
be more sensitive to changes when compared to the 10MWT.
Therefore, it might be the preferred instrument of choice when
compared to the 10MWT.
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Patient stopped test/patient did not reach cone in time/patient walked all 150 shuttles*
Reason test termination:
Speed Time Score Speed Time Score Speed Time Score
3 km/h 00:00:00 0 5 km/h 00:08:05 51 6.5 km/h 00:13:58 105
(LEVEL 1) 0:00:12 1 (LEVEL 5) 00:08:12 52 (LEVEL 8) 00:14:03 106
0:00:24 2 00:08:19 53 00:14:09 107
0:00:36 3 00:08:27 54 00:14:14 108
0:00:48 4 00:08:34 55 00:14:20 109
0:01:00 5 00:08:41 56 00:14:25 110
0:01:12 6 00:08:48 57 00:14:31 111
0:01:24 7 00:08:55 58 00:14:36 112
0:01:36 8 00:09:03 59 00:14:42 113
0:01:48 9 00:09:11 60 00:14:47 114
3.5 km/h 0:02:00 10 00:09:18 61 00:14:53 115
(LEVEL 2) 0:02:10 11 00:09:25 62 00:14:58 116
0:02:20 12 00:09:32 63 00:15:04 117
0:02:30 13 00:09:40 64 00:15:09 118
0:02:40 14 00:09:47 65 00:15:15 119
0:02:50 15 00:09:54 66 00:15:20 120
0:03:00 16 5.5 km/h 00:10:01 67 00:15:26 121
0:03:10 17 (LEVEL 6) 00:10:07 68 00:15:31 122
0:03:20 18 00:10:14 69 00:15:37 123
0:03:30 19 00:10:20 70 00:15:42 124
0:03:40 20 00:10:27 71 00:15:48 125
0:03:50 21 00:10:33 72 00:15:53 126
4 km/h 0:04:00 22 00:10:40 73 7 km/h 00:15:59 127
(LEVEL 3) 00:04:09 23 00:10:46 74 (LEVEL 9) 00:16:04 128
00:04:17 24 00:10:53 75 00:16:09 129
00:04:26 25 00:11:00 76 00:16:14 130
00:04:35 26 00:11:06 77 00:16:20 131
00:04:44 27 00:11:12 78 00:16:25 132
00:04:53 28 00:11:19 79 00:16:30 133
00:05:02 29 00:11:25 80 00:16:35 134
00:05:11 30 00:11:32 81 00:16:40 135
00:05:20 31 00:11:38 82 00:16:45 136
00:05:29 32 00:11:45 83 00:16:50 137
00:05:38 33 00:11:51 84 00:16:56 138
00:05:47 34 6 km/h 00:11:58 85 00:17:01 139
00:05:56 35 (LEVEL 7) 00:12:04 86 00:17:06 140
4.5 km/h 00:06:05 36 00:12:10 87 00:17:11 141
(LEVEL 4) 00:06:13 37 00:12:16 88 00:17:16 142
00:06:21 38 00:12:22 89 00:17:22 143
00:06:29 39 00:12:28 90 00:17:27 144
00:06:37 40 00:12:34 91 00:17:32 145
00:06:45 41 00:12:40 92 00:17:38 146
00:06:53 42 00:12:46 93 00:17:43 147
00:07:01 43 00:12:52 94 00:17:48 148
00:07:09 44 00:12:58 95 00:17:53 149
00:07:17 45 00:13:04 96 00:17:59 150
00:07:25 46 00:13:10 97
00:07:33 47 00:13:16 98
00:07:41 48 00:13:22 99
00:07:49 49 00:13:28 100
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